Relatlimab Plus Nivolumab Improves PFS in Patients With Previously Untreated Metastatic or Unresectable Melanoma

On this episode, we’ll hear about a combination therapy that improved progression-free survival (PFS) in previously untreated patients with melanoma. Then, we’ll hear about a report that looked into the effects of prior radiotherapy on the development of adverse events in patients treated with immune checkpoint inhibitors.

---